跳至主要内容
临床试验/NCT04380077
NCT04380077进行中(未招募)不适用

Gas Tamponade for Prevention of Postoperative Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Randomized Clinical Trial

Rush Eye Associates1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2020年5月15日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
150
试验地点
1
主要终点
postoperative vitreous hemorrhage rate

研究概览

简要总结

Hypothesis: Patients undergoing pars plana vitrectomy for the indication of diabetic vitreous hemorrhage will have a lower incidence of postoperative vitreous hemorrhaging during the 6-month trial period when vitreous substitution with 20-30% sulfur hexafluoride gas is utilized compared to vitreous substitution with balanced salt solution.

详细描述

Subjects enrolled into the study are randomized into one of the ensuing treatment cohorts: Group A patients undergo vitreous substitution with 20-30% sulfur hexafluoride (SF6) gas during PPV, whereas Group B patients undergo vitreous substitution with balanced salt solution (BSS) during PPV. Simple randomization allocates patients into treatment groups during PPV. Once all relevant maneuvers are completed by the surgeon prior to vitreous substitution, a simulated coin toss program decides the vitreous substitute, and therefore which group the patient enters. Randomization intraoperatively mitigates against selection bias of utilized surgical maneuvers such as endodiathermy on the part of the surgeon and allows for subjects to not undergo randomization in cases where intraoperative retinal breaks occur that would preclude the subject from receiving vitreous substitution with BSS.

Subjects undergo data collection at 3 postoperative visits: 1) 15 +/- 5 days following PPV, 2) 40 +/- 10 days following PPV, and 3) 185 +/- 15 days following PPV. Study subjects are evaluated at non-study times at the judgment of the examiner.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

盲法说明

The operating surgeons did not participate in the preoperative or postoperative care of the patient, including the data collection.

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •The patient has medically-managed type I or II diabetes mellitus.
  • •The age of the patient is > 18 years old,
  • •Snellen best-corrected visual acuity is from 20/40 to hand motions at one foot in the subject's study eye
  • •Proliferative diabetic retinopathy with a clinically evident vitreous hemorrhage of duration of at least one month by subjective history is present in the subject's study eye.
  • •The vitreous hemorrhage is symptomatic and primarily responsible for the patient's reduced vision in the judgement of the examiner.
  • •Grade 0 or I vitreoretinal adhesion according to the classification system described by Ahn et al [@] in the study eye is clinically present.
  • •Ahn J, Woo SJ, Chung H, et al. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 2011; 118: 2218-2226.

排除标准

  • •The subject's study eye previously underwent anterior or posterior vitrectomy.
  • •A lens or cornea opacity is thought to be responsible for two or more lines of reduced visual acuity in the subject's study eye (cataract, corneal scar, ectasia, etc.).
  • •Optic nerve or retina disease otherwise not related to diabetes mellitus is thought to be responsible for two or more lines of reduced visual acuity in the subject's study eye (optic neuritis, macular degeneration, glaucoma, epiretinal membrane, etc.).
  • •A non-ocular cause (i.e. cerebrovascular accident) or amblyopia is thought to be responsible for two or more lines of reduced visual acuity in the subject's study eye
  • •Neovascular glaucoma with a high intraocular pressure ( > 30 mm Hg) is discovered in the subject's study eye.
  • •Medically uncontrolled systemic hypertension (systolic > 200 mmHg or diastolic > 120 mmHg) is present.

研究组 & 干预措施

sulfur hexafluoride gas

Experimental

vitreous substitution with 20-30% sulfur hexafluoride gas during vitrectomy

干预措施: vitrectomy with sulfur hexafluoride gas (Procedure)

balanced salt solution

Active Comparator

vitreous substitution with balanced salt solution during vitrectomy

干预措施: vitrectomy with balanced salt solution (Procedure)

结局指标

主要结局

postoperative vitreous hemorrhage rate

时间窗: 6 months

incidence of postoperative vitreous hemorrhage between cohorts

次要结局

  • visual acuity(6 months)
  • unplanned vitrectomy rate(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sloan W. Rush, MD

Physician

Rush Eye Associates

研究点 (1)

Loading locations...

相似试验